Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.
CVS Health made headlines this week following the announcement that it will take over Aetna. The partnership has voiced its vision of reshaping healthcare by creating a community-based health model, according to an article in Modern Healthcare. The article, which put a focus on lower costs of care in retail clinics, highlighted a peer-reviewed study published in The American Journal of Managed Care® (AJMC®). The study, “Quality of Care at Retail Clinics for 3 Common Conditions,” found that the quality of care for minor ailments from MinuteClinics in CVS pharmacies was equal to or better than care offered from ambulatory-care facilities and emergency departments.
An article in Healio on cardiovascular screenings highlighted an AJMC® peer-reviewed study from our November issue when discussing trends following the implementation of the Affordable Care Act (ACA). The study, “Changes in Cardiovascular Care Provision After the Affordable Care Act,” found that screening for cardiovascular risks such as diabetes, smoking, and high blood pressure increased after the ACA was enacted. The study also found that men were more likely than women to be prescribed aspirin as preventive therapy.
The National Pharmaceutical Council’s Wednesday CER Daily Newsfeed included an AJMC® article on the effects of filgrastim and its biosimilar filgrastim-sndz. The article, “Filgrastim and biosimilar filgrastim-sndz Equally Efficient in Preventing Febrile Neutropenia,” found that there were no significant differences between the biosimilar and its reference biologic in the prevention of febrile neutropenia events that require hospitalization. However, noninferiority could not be established for serious adverse events.
A new peer-reviewed study published this week in AJMC® was mentioned in Science Daily’s article on money-saving plans doing little to curb spending on unnecessary medical services. While reporting findings that consumer-directed health plans (CDHPs) have little to no effect on curbing spending on 26 services deemed low value, the article referenced the study, “Impact of Consumer-Directed Health Plans on Low-Value Healthcare.” The study found that switching to CDHPs did not reduce spending on low-value healthcare services, and CDHPs may encourage patients to curb spending indiscriminately rather than specifically reducing low-value services.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Real-World Study Reveals Key Insights Into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More